Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Center for Genomics, |
RCV000768064 | SCV000898926 | uncertain significance | Combined immunodeficiency due to partial RAG1 deficiency; Combined immunodeficiency with skin granulomas; Histiocytic medullary reticulosis; Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-positive | 2021-03-30 | criteria provided, single submitter | clinical testing | RAG1 NM_000448.2 exon 2 p.Met183Ile (c.549G>A): This variant has not been reported in the literature but is present in 0.03% (12/33574) of Latino alleles in the Genome Aggregation Database (http://gnomad.broadinstitute.org/variant/11-36595403-G-A). This variant amino acid Isoleucine (Ile) is present in >20 species and is not well conserved among evolutionarily distant species; this suggests that this variant may not impact the protein. Additional computational prediction tools do not suggest an impact. In summary, data on this variant is insufficient for disease classification. Therefore, the clinical significance of this variant is uncertain. |
Labcorp Genetics |
RCV002536598 | SCV003466288 | uncertain significance | Combined immunodeficiency with skin granulomas; Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-positive | 2022-07-01 | criteria provided, single submitter | clinical testing | This sequence change replaces methionine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 183 of the RAG1 protein (p.Met183Ile). This variant is present in population databases (rs750394886, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with RAG1-related conditions. ClinVar contains an entry for this variant (Variation ID: 626003). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt RAG1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004958080 | SCV005491141 | uncertain significance | Inborn genetic diseases | 2024-07-31 | criteria provided, single submitter | clinical testing | The c.549G>A (p.M183I) alteration is located in exon 2 (coding exon 1) of the RAG1 gene. This alteration results from a G to A substitution at nucleotide position 549, causing the methionine (M) at amino acid position 183 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |